Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Complications

Brain Activation During Working Memory Is Altered in Patients With Type 1 Diabetes During Hypoglycemia

  1. Nicolas R. Bolo1,2,3⇓,
  2. Gail Musen3,4,
  3. Alan M. Jacobson3,4,5,
  4. Katie Weinger3,4,
  5. Richard L. McCartney4,
  6. Veronica Flores4,
  7. Perry F. Renshaw1,3,6 and
  8. Donald C. Simonson7,8
  1. 1Brain Imaging Center, McLean Hospital, Belmont, Massachusetts
  2. 2Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  3. 3Department of Psychiatry, Harvard Medical School, Boston, Massachusetts
  4. 4Research Division, Joslin Diabetes Center, Boston, Massachusetts
  5. 5Research Institute, Winthrop-University Hospital, Mineola, New York
  6. 6Department of Psychiatry, University of Utah, Salt Lake City, Utah
  7. 7Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Boston, Massachusetts
  8. 8Department of Medicine, Harvard Medical School, Boston, Massachusetts
  1. Corresponding author: Nicolas R. Bolo, nbolo{at}bidmc.harvard.edu.
Diabetes 2011 Dec; 60(12): 3256-3264. https://doi.org/10.2337/db11-0506
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE To investigate the effects of acute hypoglycemia on working memory and brain function in patients with type 1 diabetes.

RESEARCH DESIGN AND METHODS Using blood oxygen level–dependent (BOLD) functional magnetic resonance imaging during euglycemic (5.0 mmol/L) and hypoglycemic (2.8 mmol/L) hyperinsulinemic clamps, we compared brain activation response to a working-memory task (WMT) in type 1 diabetic subjects (n = 16) with that in age-matched nondiabetic control subjects (n = 16). Behavioral performance was assessed by percent correct responses.

RESULTS During euglycemia, the WMT activated the bilateral frontal and parietal cortices, insula, thalamus, and cerebellum in both groups. During hypoglycemia, activation decreased in both groups but remained 80% larger in type 1 diabetic versus control subjects (P < 0.05). In type 1 diabetic subjects, higher HbA1c was associated with lower activation in the right parahippocampal gyrus and amygdala (R2 = 0.45, P < 0.002). Deactivation of the default-mode network (DMN) also was seen in both groups during euglycemia. However, during hypoglycemia, type 1 diabetic patients deactivated the DMN 70% less than control subjects (P < 0.05). Behavioral performance did not differ between glycemic conditions or groups.

CONCLUSIONS BOLD activation was increased and deactivation was decreased in type 1 diabetic versus control subjects during hypoglycemia. This higher level of brain activation required by type 1 diabetic subjects to attain the same level of cognitive performance as control subjects suggests reduced cerebral efficiency in type 1 diabetes.

Acute episodes of hypoglycemia are a rate-limiting adverse effect in the treatment of type 1 diabetes. When severe, they can lead to seizures and coma (1). Even mild to moderate hypoglycemia is known to impair cognitive functions, such as working memory (2,3). Working memory is used to actively maintain and manipulate information over a brief period of time and to allocate attentional resources among competing subtasks (4,5). Traditionally, working-memory performance is thought to depend primarily on a network of brain regions, including portions of the frontal and parietal lobes, thalamus, precuneus, cerebellum, and insula (6,7).

Using blood oxygen level–dependent (BOLD) functional magnetic resonance imaging (fMRI), we evaluated how diabetes impacts these neural processes under euglycemic and hypoglycemic conditions when subjects were presented with a working-memory task (WMT). Diabetes is known to negatively affect working memory (8). This task evaluates functional effects that might reflect changes in brain structure and/or presage decreases in cognitive performance. A better understanding of the brain’s metabolic and physiological mechanisms underlying the cognitive functions implicated in working memory could lead to improved treatment strategies to help maintain cortical function in patients with diabetes during hypoglycemia (9).

BOLD fMRI is a well-established method for examining regional brain activation in response to physiological, pharmacological, sensory, or cognitive tasks (10). Studies that have examined brain activation in response to sensory stimulation or cognitive challenges using BOLD fMRI during hypoglycemic conditions in nondiabetic subjects (11–13) have shown that hypoglycemia reduces regional brain BOLD activation. This reduction in BOLD response during hypoglycemia has been attributed to low glucose levels causing decreases in neuronal activity, glucose oxidative metabolism, cerebral blood flow, neurovascular coupling, and/or neuronal recruitment (12).

Whether cognitive function in patients with type 1 diabetes is affected by hypoglycemia in the same manner as in nondiabetic individuals remains unclear because few studies using functional neural imaging have directly compared diabetic and nondiabetic subjects during the performance of cognitive tasks (14,15). If brain glucose transport or metabolism are altered in type 1 diabetes, as has been suggested in recent studies by our group (16) and others (17), then one would expect that the BOLD activation response during hypoglycemia may differ between diabetic patients compared with nondiabetic control subjects. On the basis of these findings, we hypothesized that 1) patients with type 1 diabetes would have greater BOLD activation during the performance of a WMT during hypoglycemia when compared with nondiabetic control subjects, 2) cognitive performance would deteriorate during hypoglycemia in both groups, and 3) among type 1 diabetic patients, better glycemic control (lower HbA1c) would correlate with BOLD activation responses to the WMT during hypoglycemia. We also conducted exploratory analyses to examine deactivation patterns in the default-mode network (DMN), the regions of the brain that are more active during rest (18), because of other research by our group examining the effects of diabetes on deactivation patterns during cognitive tasks and previous research suggesting that DMN function may be altered in diseases that affect cognition, such as Alzheimer’s disease (19).

RESEARCH DESIGN AND METHODS

The study sample consisted of 16 patients with type 1 diabetes and 16 healthy control subjects from an ongoing study of brain function during hypoglycemia in type 1 diabetes. Data from five type 1 diabetic and five control subjects were included in a previous publication (20). Demographic and clinical characteristics of the subjects are presented in Table 1. The patients’ number of self-reported hypoglycemic episodes (plasma glucose <3.9 mmol/L with concomitant symptoms) in the month preceding the initial visit averaged eight episodes (range 2–28). Patients with autonomic neuropathy (assessed by standard criteria ) (21), painful peripheral neuropathy, urinary albumin levels >300 mg/day, or proliferative retinopathy by review of medical records, physical exam, or self-report were excluded from the study. Other exclusion criteria were a history of psychosis or schizophrenia; cocaine, heroin, or alcohol dependence; and any contraindications to MRI, such as metallic implants, pregnancy, or claustrophobia.

View this table:
  • View inline
  • View popup
TABLE 1

Demographic and clinical characteristics of study subjects

Following approval from the institutional review boards of both the Joslin Diabetes Center (where patients were recruited) and the McLean Hospital (where the MRI was performed), patients provided the following information during screening: self-report of their lifetime experience of severe hypoglycemic events leading to unconsciousness (22); psychiatric history; handedness; medical history; and current medications.

Of 18 control participants who were eligible for the study, 2 were excluded from analysis because of excessive head motion during the fMRI by applying exclusion criteria of translations in excess of 3 mm in x, y, or z directions or rotations in excess of 3° around the x, y, or z axes. No diabetic subjects were excluded for head motion.

Experimental protocol.

The experimental protocol is described elsewhere (20) and briefly reviewed below. On the day before the study, patients with type 1 diabetes had a continuous glucose monitor (CGM System Gold; Medtronic, Northridge, CA) inserted. If the continuous glucose monitor showed glucose <3.3 mmol/L, the study was postponed to a later date. The experiment used the insulin clamp technique with four successive time periods corresponding to different plasma glucose levels: baseline (30 min); euglycemic clamp (40 min, target glucose 5.0 mmol/L); declining glycemia (40 min, plasma glucose reduced from 5.0 to 2.8 mmol/L); and hypoglycemic clamp (30 min, target glucose 2.8 mmol/L). Anatomical MRI was performed during baseline, and fMRI was performed during the euglycemic and hypoglycemic periods while the WMT was administered (Fig. 1).

FIG. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 1.

Study protocol. Time line of structural and functional scans, WMTs, and periods of euglycemia (nominal 5.0 mmol/L), glucose descent, and hypoglycemia (nominal 2.8 mmol/L).

Insulin clamp technique.

An intravenous catheter was inserted into an antecubital vein for the administration of insulin and glucose, and a second catheter was inserted into a distal forearm or hand vein for the withdrawal of blood samples. A heated gel pack was used to warm the hand to arterialize the venous blood. After the baseline period, regular human insulin was infused at 12 pmol/kg per min for 110 min. The plasma glucose levels were maintained at the desired level by infusion of 20% dextrose using a negative-feedback algorithm, as previously described (23–25). After the euglycemic clamp period (40 min), the glucose infusion rate was reduced to allow the plasma glucose level to decline by 2.2 mmol/L (from 5.0 to 2.8 mmol/L) over the next 40 min, followed by the 30-min hypoglycemic clamp period. During the entire clamp protocol, glucose levels were measured every 5 min, and counterregulatory hormones (epinephrine, cortisol, growth hormone, and glucagon) were measured every 10 min. At the end of the protocol, the insulin infusion was discontinued, the glucose infusion was increased to restore euglycemia, and the subjects were given a meal and discharged.

Hormone and substrate assays.

Plasma glucose was measured using the glucose oxidase method. Serum insulin and growth hormone and plasma epinephrine were measured by enzyme-linked immunosorbent assay. Plasma glucagon and cortisol were measured by radioimmunoassay.

WMT.

The task stimuli were administered using Presentation software (Neurobehavioral Systems, Albany, CA). The images were projected on a backlit screen that was visualized from within the magnet bore by a mirror mounted on the head coil. Response times and errors were collected using a magnetic resonance–compatible hand-held four-button fiberoptic response pad (FORP; Current Designs, Philadelphia, PA) connected to the PC by an optical cable interface. The stimulus presentation was synchronized with the fMRI acquisition sequence at the beginning of each trial by the interface that responded to scanner-generated trigger signals. The WMT was administered 15–20 min after the beginning of the euglycemic period and again at 15–20 min after the beginning of the hypoglycemic period (Fig. 1). Subjects performed practice tests before the study to achieve familiarity with the test procedure, and we used randomly assigned counterbalanced forms of the test during euglycemia and hypoglycemia to minimize learning.

During the WMT, adapted from Rypma et al. (26), participants viewed a string of six digits for 1,200 ms followed by a 2,000-ms unfilled retention interval (blank screen). Then, one digit was displayed on the computer monitor for 1,500 ms, and the subject had 1,300 ms to decide whether the digit was a member of the previously seen string. Using the same timing parameters, a matched control task was used in which subjects viewed six percent symbols (%) on the screen, followed by the unfilled retention interval, followed by a right- or a left-pointing arrow. The participants were asked to press the response key corresponding to the direction of the arrow. In the rest task, participants fixated on a plus (+) sign for 30 s. Each of these three tasks (WMT, matched control, and rest) was presented four times in a block design for a total of 6 min of testing. There were 5 memory-scanning trials per block for a total of 20 memory-scanning trials.

MRI acquisition methods.

All magnetic resonance images were acquired with a 3.0 Tesla Siemens Trio scanner (Siemens, Erlangen, Germany), using a circularly polarized birdcage radiofrequency head coil tuned to the proton frequency. Global field uniformity was adjusted at the beginning of each scanning session using Siemens’ automated shimming routines. A three-dimensional, T1-weighted anatomical image was acquired using a magnetization-prepared, rapid-acquisition gradient echo sequence (TR/TE = 2,100/2.74 ms; spatial resolution = 1 × 1 × 1.3 mm3; matrix size = 256 × 256 × 128) and used for functional image registration. BOLD fMRI images covering the whole brain were acquired in the axial plane using an echo planar imaging (EPI) sequence (TR/TE = 3,000/30 ms; 26 slices acquired in interleaved scanning order; slice thickness = 5 mm; field of view = 200 × 200 mm2; matrix size = 64 × 64), with an in-plane resolution of 3.125 × 3.125 mm2. One multislice EPI volume covering the whole brain was acquired every 3 s for a total of 120 volumes for the 6-min fMRI run.

Image processing.

Image processing and analyses were performed using the FSL software package (Analysis Group, FMRIB, Oxford, U.K.) running on a Mac-Pro Quad-Core Intel-Xeon computer (Apple, Cupertino, CA). All brain images were registered to the standard MNI-152 brain (Montreal Neurologic Institute) to allow multisubject analyses in standardized space and identification of all regions of interest. The first two EPI volumes of each functional run were discarded to allow for T1 equilibration. Prestatistical processing of EPI time series consisted of motion correction, slice scan-time correction, nonbrain removal, spatial smoothing with a 6-mm full-width at half-maximum three-dimensional Gaussian filter, linear trend removal, and a temporal high-pass filter with a cutoff of 120 s. Functional data were overlaid on the MNI-152 brain.

Data analyses.

Regional brain activations and deactivations in response to the WMT were examined by performing a first-level general linear model (GLM) multiple regression analysis for each subject and glycemic condition. Model predictors for BOLD signal time courses were the boxcar time courses for each task stimulus paradigm convolved with a γ function to account for hemodynamic response. Predictors for the temporal derivatives of the task paradigm were added to the design matrix to improve the fit to the data by allowing for potential misspecification of the hemodynamic delay (27). The model for the baseline rest condition predictor was a constant function.

To compare activation and deactivation patterns between groups and conditions, higher-level multisubject mixed-effects GLM analyses compared multiple regression correlation coefficients associated with each model predictor for each brain voxel for each subject under each condition. Activations were computed by contrasting the WMT task to its control task. Deactivations were computed by contrasting the WMT task to the rest period. These higher-level analyses were performed using FSL’s local analysis of mixed effects stage 1. Resulting Z score (i.e., Gaussianized T/F) statistic images were thresholded using clusters determined by Z > 2.3 and a corrected cluster significance threshold of P = 0.05 (28). These statistical parametric maps yield the clusters of adjacent brain voxels of regional activation or deactivation from which we computed a single brain volume of activation or deactivation at the set statistical significance threshold (P < 0.05).

To investigate the variation of the regional percent BOLD signal change, we applied a region-of-interest (ROI) analysis in the superior parietal lobule (SPL) region, which had significant activation differences during hypoglycemia. To define the ROI, we created a binary mask of the SPL region provided by the probabilistic Harvard-Oxford Cortical Structural Atlas (29) thresholded at the 50% probability level. The ROI analysis was performed using FSL’s FEATQUERY tool to extract the average time courses of parameter estimates of the percent BOLD signal change from all voxels contained in the SPL mask.

To investigate the association of WMT activation and deactivation to glycemic control in type 1 diabetes, we performed the mixed-effects GLM group analyses while including HbA1c values as a covariate in the design matrix. To compute the regional coefficients of correlation of activation to HbA1c, the average percent BOLD activation values were extracted from the regions of significant correlation in type 1 diabetes during hypoglycemia using the FEATQUERY tool.

Standard statistical tests, including t tests for paired and unpaired data as appropriate, and ANOVA were used to compare glucose and counterregulatory hormone levels between diabetic and nondiabetic subjects during euglycemia and hypoglycemia. All data are presented as means ± SEM, unless otherwise specified, and statistical tests were conducted using a two-sided α level of 0.05.

RESULTS

Plasma glucose and counterregulatory hormones.

Average plasma glucose levels during the euglycemic period for nondiabetic control and type 1 diabetic subjects were 5.0 ± 0.4 mmol/L and 5.0 ± 0.6 mmol/L, respectively. During the hypoglycemic period, average glucose levels for the two groups were 2.8 ± 0.2 mmol/L and 2.7 ± 0.1 mmol/L, respectively. There was no significant difference between groups and no significant interaction between the glycemic condition and group. Mean counterregulatory hormone levels during baseline and euglycemia and peak levels attained during hypoglycemia are shown in Fig. 2. Glucagon and epinephrine secretion were lower in the type 1 diabetic patients during hypoglycemia compared with control subjects.

FIG. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 2.

Plasma levels of counterregulatory hormones (error bars ± SE) during the baseline and euglycemic periods and at the end of the hypoglycemic period in control subjects and patients with type 1 diabetes (T1DM). EU, euglycemia; HYPO, hypoglycemia. P values for statistically significant comparisons: *P < 0.05 vs. baseline; †P < 0.05 vs. euglycemia; ‡P < 0.01 vs. baseline; §P < 0.01 vs. euglycemia; •P < 0.05 vs. control subjects; ¶P < 0.001 vs. control subjects.

Cognitive performance.

Type 1 diabetic and control subjects did not differ in accuracy or reaction time during the WMT at either euglycemia or hypoglycemia. During euglycemia, control subjects achieved 85 ± 2% correct, with a reaction time of 1,133 ± 54 ms, whereas type 1 diabetic patients had 85 ± 4% correct, with a reaction time of 1,200 ± 57 ms. At hypoglycemia, control subjects had 84 ± 5% correct, with a reaction time of 1,122 ± 57 ms, whereas type 1 diabetic patients had 85 ± 4% correct, with a reaction time of 1,204 ± 58 ms. There were no significant within-subject differences for either group when comparing the performance between glycemic conditions and no interaction between group and condition.

Functional imaging.

Brain activations in response to the WMT for each subject group during each glycemic condition are shown in Fig. 3. The regions of greater BOLD activation for the WMT relative to the control task (P < 0.05, corrected for multiple comparisons using the cluster-based threshold method) (28) are indicated in a red-to-yellow color scale overlaid on the gray scale standard MNI-152 T1-weighted anatomical brain atlas. For both subject groups during both glycemic conditions, the WMT activated brain regions located in bilateral medial superior frontal gyrus, left precentral gyrus, bilateral SPL, bilateral middle frontal gyrus, bilateral anterior cingulate cortex, bilateral insula, left supramarginal gyrus, bilateral thalamus, bilateral inferior occipital cortex, and bilateral cerebellum.

FIG. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 3.

BOLD activation during the WMT in control and type 1 diabetic (T1DM) subjects during euglycemia and hypoglycemia. Statistical parametric maps of regions of greatest activation during WMTs vs. control tasks for each subject group and glycemic condition. Functional activations (red-to-yellow color scale) are overlaid on the MNI-152 standard brain anatomy (gray scale). The threshold for activation was P < 0.05 after correction for multiple comparisons using the cluster-based threshold method (see research design and methods). During hypoglycemia, type 1 diabetic subjects exhibit greater activation than control subjects during the WMT. (A high-quality digital representation of this figure is available in the online issue.)

During euglycemia, the overall extent of activation was similar in the diabetic patient and control groups, with activated brain volumes of 613 and 498 cm3, respectively. During hypoglycemia, the extent of regional BOLD activation decreased relative to euglycemia in both subject groups; however, it decreased less in patients with diabetes than in control subjects (P < 0.05). The regional patterns of activation also differed between groups. In type 1 diabetes, activation decreased mostly in the insula, whereas for control subjects, activation decreased mostly in the cerebellum. Regions with higher activation in type 1 diabetes during hypoglycemia include the bilateral SPL, bilateral posterior supramarginal gyrus, bilateral anterior and posterior cingulate gyrus, left inferior frontal gyrus and posterior middle temporal gyrus, right hippocampus, and the cerebellum. Thus, during hypoglycemia, activation volumes were 80% larger in type 1 diabetic versus control subjects, with activation volumes of 431 and 239 cm3, respectively (P < 0.05). The extended activation volume in type 1 diabetic relative to control subjects during hypoglycemia was mainly a result of maintenance of a higher percent BOLD activation during the WMT, as illustrated in Fig. 4, which compares the time courses of the percent BOLD signal estimates averaged over the SPL region for each subject group under each glycemic condition.

FIG. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 4.

Percent BOLD activation by ROI analysis during the WMT during euglycemia (left) and hypoglycemia (right). Upper: Location of the superior parietal lobule (SPL, association cortex including Brodmann areas 7 and 40) region used for ROI analysis is indicated at the intersection of the crosshairs on the activation maps for each subject group overlaid on the MNI-152 standard brain. Lower: Plots of the time courses of change in percent BOLD activation in the SPL ROI during the fMRI WMT. Percent change was measured relative to BOLD activation during the control task and averaged over all pixels in the ROI and all subjects within each subject group. The colored strip above the horizontal time axis shows the time sequence of task conditions. CONT, control task; REST, resting state task. (A high-quality digital representation of this figure is available in the online issue.)

Regional brain deactivations in response to the WMT for each subject group during each glycemic condition are shown in Fig. 5. Regions of lesser BOLD activation (or more deactivation) for WMT relative to the resting task (P < 0.05, corrected for multiple comparisons using the cluster-based threshold method) (28) are indicated in a dark blue–to–light blue color scale overlaid on the standard MNI-152 T1-weighted anatomical brain atlas in gray scale, along with activations in red to yellow. During euglycemia, WMT deactivated brain regions located in bilateral medial frontal cortex, posterior cingulate cortex, and superior lateral occipital cortex for both groups. The extent of deactivation was similar in the type 1 diabetic and control groups, with only a 10% difference between groups. Overall, deactivated brain volumes were 45 and 41 cm3, respectively. During hypoglycemia, the extent of regional BOLD deactivation decreased relative to euglycemia in both subject groups; however, it decreased more for patients with type 1 diabetes (P < 0.05) (i.e., they were unable to significantly deactivate these regions).

FIG. 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 5.

BOLD activation and deactivation during the WMT in type 1 diabetic (T1DM) and control subjects during euglycemia and hypoglycemia. Statistical parametric maps of regions of greatest activation during WMTs vs. control tasks (functional activations in the red-to-yellow color scale) and regions of decreased activation during the WMTs vs. resting tasks (functional deactivations in the blue color scale) are overlaid on the MNI-152 standard brain anatomy (gray scale). The threshold for activations and deactivations was P < 0.05 after correction for multiple comparisons using the cluster-based threshold method (see research design and methods). During hypoglycemia, patients with type 1 diabetes exhibit less deactivation than control subjects. (A high-quality digital representation of this figure is available in the online issue.)

The regional patterns of decreased deactivation also differed between groups (Fig. 5). For patients with type 1 diabetes, deactivation decreased mostly in the medial frontal and posterior cingulate cortices, whereas for control subjects, deactivation decreased mostly in the posterior cingulate cortex. Control subjects also had small deactivation volumes in the cerebellum (right crus II) during hypoglycemia only. Thus, during hypoglycemia, the extent of deactivation was almost 70% smaller in type 1 diabetic relative to control subjects, with deactivation volumes of 5 cm3 located in the superior lateral occipital cortex for patients and 17 cm3 located mainly in the medial frontal and superior lateral occipital cortices for control subjects (P < 0.05).

Finally, we examined the relationship of HbA1c levels with activation patterns in type 1 diabetes by entering HbA1c as a covariate into the GLM. We found that lower HbA1c levels were associated with higher activation in the right parahippocampal gyrus and the amygdala (Fig. 6) during hypoglycemia. We also found that HbA1c levels were not associated with deactivation.

FIG. 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 6.

Regions of BOLD activation inversely correlated with HbA1c in patients with type 1 diabetes. Upper: Statistical parametric map of the correlation of WMT activation with HbA1c in patients with type 1 diabetes during hypoglycemia (P < 0.05). Sagittal, coronal, and axial slices (from left to right) showing activation correlation in a red-to-yellow scale overlaid on the MNI-152 standard brain anatomy (gray scale). These HbA1c-correlated activation clusters were identified in the right parahippocampal gyrus and amygdala using the Harvard-Oxford Cortical Structural Atlas. Lower: Plots of regional percent BOLD activation vs. HbA1c for patients with type 1 diabetes during euglycemia (left) and hypoglycemia (right). Filled circles with error bars: average percent BOLD activation for each patient ± SD within the region of activation. The line is the linear regression best fit of the data with its correlation coefficient R2. (A high-quality digital representation of this figure is available in the online issue.)

DISCUSSION

This study demonstrates that patients with type 1 diabetes show a different pattern of brain activation in response to a WMT than do nondiabetic control subjects during hypoglycemia. Specifically, we found that for patients with type 1 diabetes during hypoglycemia, WMT-related activation responses were increased in several cortical regions, including the parietal and frontal cortices, hippocampus, and cerebellum. Task-induced deactivations, typically observed in the DMN during cognitive effort, were significantly suppressed during hypoglycemia in bilateral medial-frontal and posterior cingulate cortices for type 1 diabetic patients compared with control subjects. Activation and deactivation patterns were similar across groups during euglycemia. Behavioral performance on the WMT was similar across groups and conditions. Finally, HbA1c was inversely correlated with WMT activation during hypoglycemia in the right parahippocampal gyrus and amygdala, two areas that have been reported to activate in memory-disordered populations as a form of compensatory recruitment (30–32).

The regional BOLD activations we observed in response to the WMT were compatible with those found in other fMRI studies of similar WMTs (5,26,33–35). Although the main regions that help govern working memory are the dorsolateral and medial prefrontal cortices and anterior cingulate cortex, other regions, such as the parietal lobe (36) and cerebellum (37), are known to play supplementary roles. These regions were activated more in type 1 diabetic patients than in control subjects during hypoglycemia, suggesting that supplementary brain regions may have been recruited to help preserve cognitive performance. The failure to suppress activation in the DMN also is consistent with an interpretation that type 1 diabetic patients need to recruit more brain resources for cognitive preservation (11). Similar patterns of increased activation and decreased deactivation have been observed with mild cognitive impairment (30) and in older individuals at risk for Alzheimer’s disease (38), suggesting, in these cases, a compensatory response to accumulating pathology.

Cognitive performance was not altered by hypoglycemia in either subject group. Although some studies have shown similar results for less challenging WMTs (39), others have shown severe impairment during hypoglycemia for highly challenging WMTs involving reasoning (2). Of importance, a number of studies have used the same Sternberg WMT used here to evaluate differences in brain activation patterns across different populations (40,41). In our study, different brain activation patterns, despite similar cognitive performance across groups, suggest unique strategies of brain recruitment used across groups to augment performance during the glycemic challenge.

Our results showing hyperactivation of brain regions in type 1 diabetic patients with low HbA1c and hypoactivation in patients with higher HbA1c could reflect upregulation of glucose transport in the brain, as seen in patients with good glycemic control (42,43). Type 1 diabetic patients may engage more brain regions to maintain the same performance to compensate for cerebral inefficiency attributed to reduced brain resources (44). These results also are consistent with the patterns observed in many physiologic systems in which a period of compensatory hyperfunction precedes functional decline and ultimate organ-system failure.

In an earlier report from our group, we demonstrated that type 1 diabetic patients showed reduced gray-matter density in the parahippocampal gyrus associated with higher HbA1c (45). One possible explanation may be that gray-matter loss in this temporal region prevents its participation in the brain’s response to moderate acute hypoglycemia. Wessels et al. (46) also observed abnormal brain activity patterns in patients with diabetes retinopathy, which is more likely to be associated with elevated HbA1c levels. However, our studies differed in both design and data analytic methodology, making a direct comparison difficult.

The differences in the hypoglycemic BOLD response between patients and control subjects found in this study may be attributed to a variety of mechanisms, including preservation of global brain glucose uptake in diabetes as a result of adaptation to hypoglycemia (12,47), differences in neurovascular coupling, resting cerebral blood flow, neuronal activity linked to oxidative metabolism, increased brain glycogen stores (48), or a tendency to use nonglucose substrates to support higher neuronal activity (49). In addition, changes in brain glucose transport or metabolism, resulting in increased brain glucose levels, might occur as a result of recurrent hypoglycemia. We reported such a finding along with accompanying increases in glutamate that were correlated with decreases in memory and executive function (16). It may follow that abnormal glutamate metabolism contributed to altered neurovascular coupling in patients in our study. Although these adaptive mechanisms in type 1 diabetes may in the short-term allow compensation for altered brain activity patterns during a hypoglycemic challenge, they may presage long-term maladaptive or adverse consequences.

Although our study demonstrates greater activation during hypoglycemia in type 1 diabetes along with reduced deactivation of the DMN, the small sample size may limit the implications of our results. However, the regional BOLD activations we observed in response to the WMT were compatible with regional activations found in other fMRI studies of similar WMTs (5,26,33–35). The reductions in BOLD response observed during hypoglycemia were also compatible with other reports showing reduced brain BOLD activation in primary or association cortex in response to sensory, motor, or cognitive tasks in nondiabetic subjects (11,12,14,47). Also, this study was unable to resolve whether the alterations in brain activation were secondary to chronic hyperglycemia or recurrent hypoglycemia. Future studies can help resolve this issue.

In summary, patients with type 1 diabetes activate more brain regions than control subjects during hypoglycemia by maintaining activity from euglycemia to hypoglycemia in task-relevant regions and by failing to suppress activation in the DMN. This suggests that type 1 diabetic patients may need to recruit more brain resources to preserve cognitive performance. The pattern of hyperactivation of both the DMN and task-relevant regions is consistent with findings in disease states with impaired cognition, such as mild cognitive impairment and Alzheimer’s disease (38). There has been persistent concern about the consequences of recurrent hypoglycemia on brain structure and cognitive function. There are minimal long-term effects of recurrent hypoglycemia on cognition into middle age (50), but it is not clear whether this resiliency will last throughout the aging process. Future research should evaluate our findings as an early manifestation and warning of future clinically relevant cognitive decline. This research may guide the development of treatment regimens to enhance symptom recognition or to stabilize the neurochemical response to hypoglycemia to reduce the impact of glucodeprivation on cognitive function.

ACKNOWLEDGMENTS

This study was supported in part by National Institutes of Health grants 5R01-DK073843-03, DK-60754, DK-62218-01A1, and P30-DK-36836 (Joslin Diabetes and Endocrinology Research Center); the Herbert Graetz Fund; and grant 5M01-RR001032-32 to the Beth Israel Deaconess General Clinical Research Center.

No potential conflicts of interest relevant to this article were reported.

N.R.B., G.M., A.M.J., and K.W. researched data, contributed to discussion, and wrote, reviewed, and edited the manuscript. R.L.M. researched data, contributed to discussion, and reviewed and edited the manuscript. V.F. researched data and reviewed and edited the manuscript. P.F.R. contributed to discussion and reviewed and edited the manuscript. D.C.S. researched data, contributed to discussion, and wrote, reviewed, and edited the manuscript.

Parts of this article were presented in abstract form at the 70th Scientific Sessions of the American Diabetes Association, Orlando Florida, 25–29 June 2010, and at the 71st Scientific Sessions of the American Diabetes Association, San Diego, California, 24–28 June 2011.

The authors thank Judi Lauerman, RN, Brigham and Women's Hospital, Boston, Massachusetts, and Karen Branch, RN, Joslin Diabetes Center, Boston, Massachusetts, for their expert nursing assistance.

  • Received April 14, 2011.
  • Accepted August 25, 2011.
  • © 2011 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

REFERENCES

  1. ↵
    1. Cryer PE
    . Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002;45:937–948pmid:12136392
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Deary IJ,
    2. Sommerfield AJ,
    3. McAulay V,
    4. Frier BM
    . Moderate hypoglycaemia obliterates working memory in humans with and without insulin treated diabetes. J Neurol Neurosurg Psychiatry 2003;74:278–279pmid:12531972
    OpenUrlFREE Full Text
  3. ↵
    1. Sommerfield AJ,
    2. Deary IJ,
    3. McAulay V,
    4. Frier BM
    . Moderate hypoglycemia impairs multiple memory functions in healthy adults. Neuropsychology 2003;17:125–132pmid:12597081
    OpenUrlCrossRefPubMed
  4. ↵
    1. Wager TD,
    2. Smith EE
    . Neuroimaging studies of working memory: a meta-analysis. Cogn Affect Behav Neurosci 2003;3:255–274pmid:15040547
    OpenUrlCrossRefPubMed
  5. ↵
    1. Baddeley A
    . Working memory: looking back and looking forward. Nat Rev Neurosci 2003;4:829–839pmid:14523382
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. LaBar KS,
    2. Gitelman DR,
    3. Parrish TB,
    4. Mesulam M-M
    . Neuroanatomic overlap of working memory and spatial attention networks: a functional MRI comparison within subjects. Neuroimage 1999;10:695–704pmid:10600415
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Smith EE,
    2. Jonides J
    . Working memory: a view from neuroimaging. Cognit Psychol 1997;33:5–42pmid:9212720
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Brands AM,
    2. Biessels GJ,
    3. de Haan EH,
    4. Kappelle LJ,
    5. Kessels RP
    . The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care 2005;28:726–735pmid:15735218
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Bingham E,
    2. Rosenthal JM,
    3. Amiel SA
    . Cognitive function in acute hypoglycaemia 2. Diabetes Nutr Metab 2002;15:363–367pmid:12625485
    OpenUrlPubMed
  10. ↵
    1. Ogawa S,
    2. Tank DW,
    3. Menon R,
    4. et al
    . Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci USA 1992;89:5951–5955pmid:1631079
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Rosenthal JM,
    2. Amiel SA,
    3. Yágüez L,
    4. et al
    . The effect of acute hypoglycemia on brain function and activation: a functional magnetic resonance imaging study. Diabetes 2001;50:1618–1626pmid:11423484
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Anderson AW,
    2. Heptulla RA,
    3. Driesen N,
    4. et al
    . Effects of hypoglycemia on human brain activation measured with fMRI. Magn Reson Imaging 2006;24:693–697pmid:16824963
    OpenUrlCrossRefPubMed
  13. ↵
    1. Warren RE,
    2. Sommerfield AJ,
    3. Greve A,
    4. Allen KV,
    5. Deary IJ,
    6. Frier BM
    . Moderate hypoglycaemia after learning does not affect memory consolidation and brain activation during recognition in non-diabetic adults. Diabetes Metab Res Rev 2008;24:247–252pmid:18088081
    OpenUrlCrossRefPubMed
  14. ↵
    1. Driesen NR,
    2. Goldberg PA,
    3. Anderson AW,
    4. et al
    . Hypoglycemia reduces the blood-oxygenation level dependent signal in primary auditory and visual cortex: a functional magnetic resonance imaging study. J Neurosci Res 2007;85:575–582pmid:17154420
    OpenUrlCrossRefPubMed
  15. ↵
    1. Wessels AM,
    2. Rombouts SA,
    3. Simsek S,
    4. et al
    . Microvascular disease in type 1 diabetes alters brain activation: a functional magnetic resonance imaging study. Diabetes 2006;55:334–340pmid:16443765
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Lyoo IK,
    2. Yoon SJ,
    3. Musen G,
    4. et al
    . Altered prefrontal glutamate-glutamine-γ-aminobutyric acid levels and relation to low cognitive performance and depressive symptoms in type 1 diabetes mellitus. Arch Gen Psychiatry 2009;66:878–887
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Criego AB,
    2. Tkac I,
    3. Kumar A,
    4. Thomas W,
    5. Gruetter R,
    6. Seaquist ER
    . Brain glucose concentrations in patients with type 1 diabetes and hypoglycemia unawareness. J Neurosci Res 2005;79:42–47pmid:15578722
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Raichle ME,
    2. MacLeod AM,
    3. Snyder AZ,
    4. Powers WJ,
    5. Gusnard DA,
    6. Shulman GL
    . A default mode of brain function. Proc Natl Acad Sci USA 2001;98:676–682pmid:11209064
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Celone KA,
    2. Calhoun VD,
    3. Dickerson BC,
    4. et al
    . Alterations in memory networks in mild cognitive impairment and Alzheimer’s disease: an independent component analysis. J Neurosci 2006;26:10222–10231pmid:17021177
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Musen G,
    2. Simonson DC,
    3. Bolo NR,
    4. et al
    . Regional brain activation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab 2008;93:1450–1457pmid:18198228
    OpenUrlCrossRefPubMed
  21. ↵
    American Diabetes Association, American Academy of Neurology. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy: summary and recommendations. Diabetes Care 1992;15:1104–1107pmid:1505320
    OpenUrlFREE Full Text
  22. ↵
    The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271–286pmid:9000705
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Amiel SA,
    2. Sherwin RS,
    3. Simonson DC,
    4. Tamborlane WV
    . Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 1988;37:901–907pmid:3290007
    OpenUrlAbstract/FREE Full Text
    1. DeFronzo RA,
    2. Tobin JD,
    3. Andres R
    . Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214–E223pmid:382871
    OpenUrlPubMedWeb of Science
  24. ↵
    1. Widom B,
    2. Simonson DC
    . Glycemic control and neuropsychologic function during hypoglycemia in patients with insulin-dependent diabetes mellitus. Ann Intern Med 1990;112:904–912pmid:2187391
    OpenUrlPubMed
  25. ↵
    1. Rypma B,
    2. Prabhakaran V,
    3. Desmond JE,
    4. Glover GH,
    5. Gabrieli JD
    . Load-dependent roles of frontal brain regions in the maintenance of working memory. Neuroimage 1999;9:216–226pmid:9927550
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Beckmann CF,
    2. Jenkinson M,
    3. Woolrich MW,
    4. et al
    . Applying FSL to the FIAC data: model-based and model-free analysis of voice and sentence repetition priming. Hum Brain Mapp 2006;27:380–391pmid:16565953
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Friston KJ
    . Testing for anatomically specified regional effects. Hum Brain Mapp 1997;5:133–136pmid:10096418
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Desikan RS,
    2. Ségonne F,
    3. Fischl B,
    4. et al
    . An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968–980pmid:16530430
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Dickerson BC,
    2. Salat DH,
    3. Bates JF,
    4. et al
    . Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 2004;56:27–35pmid:15236399
    OpenUrlCrossRefPubMedWeb of Science
    1. Rosenbaum RS,
    2. Furey ML,
    3. Horwitz B,
    4. Grady CL
    . Altered connectivity among emotion-related brain regions during short-term memory in Alzheimer’s disease. Neurobiol Aging 2010;31:780–786pmid:18639365
    OpenUrlCrossRefPubMed
  30. ↵
    1. Yetkin FZ,
    2. Rosenberg RN,
    3. Weiner MF,
    4. Purdy PD,
    5. Cullum CM
    . FMRI of working memory in patients with mild cognitive impairment and probable Alzheimer’s disease. Eur Radiol 2006;16:193–206pmid:16402259
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Smith EE,
    2. Jonides J
    . Neuroimaging analyses of human working memory. Proc Natl Acad Sci USA 1998;95:12061–12068pmid:9751790
    OpenUrlAbstract/FREE Full Text
    1. Smith EE,
    2. Jonides J
    . Storage and executive processes in the frontal lobes. Science 1999;283:1657–1661pmid:10073923
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Duncan J,
    2. Owen AM
    . Common regions of the human frontal lobe recruited by diverse cognitive demands. Trends Neurosci 2000;23:475–483pmid:11006464
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Jonides J,
    2. Schumacher EH,
    3. Smith EE,
    4. et al
    . The role of parietal cortex in verbal working memory. J Neurosci 1998;18:5026–5034pmid:9634568
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Schmahmann JD,
    2. Sherman JC
    . The cerebellar cognitive affective syndrome. Brain 1998;121:561–579pmid:9577385
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Pihlajamäki M,
    2. Sperling RA
    . Functional MRI assessment of task-induced deactivation of the default mode network in Alzheimer’s disease and at-risk older individuals. Behav Neurol 2009;21:77–91pmid:19847047
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Hvidberg A,
    2. Fanelli CG,
    3. Hershey T,
    4. Terkamp C,
    5. Craft S,
    6. Cryer PE
    . Impact of recent antecedent hypoglycemia on hypoglycemic cognitive dysfunction in nondiabetic humans. Diabetes 1996;45:1030–1036pmid:8690148
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Kim MA,
    2. Tura E,
    3. Potkin SG,
    4. et al.
    ; FBIRN. Working memory circuitry in schizophrenia shows widespread cortical inefficiency and compensation. Schizophr Res 2010;117:42–51pmid:20096539
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Meda SA,
    2. Stevens MC,
    3. Folley BS,
    4. Calhoun VD,
    5. Pearlson GD
    . Evidence for anomalous network connectivity during working memory encoding in schizophrenia: an ICA based analysis. PLoS ONE 2009;4:e7911pmid:19936244
    OpenUrlCrossRefPubMed
  39. ↵
    1. Boyle PJ,
    2. Kempers SF,
    3. O’Connor AM,
    4. Nagy RJ
    . Brain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995;333:1726–1731pmid:7491135
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. McCall AL
    . Cerebral glucose metabolism in diabetes mellitus. Eur J Pharmacol 2004;490:147–158pmid:15094081
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Stern Y
    . What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002;8:448–460pmid:11939702
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    1. Musen G,
    2. Lyoo IK,
    3. Sparks CR,
    4. et al
    . Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 2006;55:326–333pmid:16443764
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Wessels AM,
    2. Simsek S,
    3. Remijnse PL,
    4. et al
    . Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia 2006;49:2474–2480pmid:16703329
    OpenUrlCrossRefPubMedWeb of Science
  44. ↵
    1. Kennan RP,
    2. Takahashi K,
    3. Pan C,
    4. Shamoon H,
    5. Pan JW
    . Human cerebral blood flow and metabolism in acute insulin-induced hypoglycemia. J Cereb Blood Flow Metab 2005;25:527–534pmid:15703703
    OpenUrlCrossRefPubMed
  45. ↵
    1. Choi IY,
    2. Seaquist ER,
    3. Gruetter R
    . Effect of hypoglycemia on brain glycogen metabolism in vivo. J Neurosci Res 2003;72:25–32pmid:12645076
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    1. Mason GF,
    2. Petersen KF,
    3. Lebon V,
    4. Rothman DL,
    5. Shulman GI
    . Increased brain monocarboxylic acid transport and utilization in type 1 diabetes. Diabetes 2006;55:929–934pmid:16567513
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Jacobson AM,
    2. Ryan CM,
    3. Cleary P,
    4. et al.
    ; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007;356:1842–1852pmid:17476010
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Diabetes: 60 (12)

In this Issue

December 2011, 60(12)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Brain Activation During Working Memory Is Altered in Patients With Type 1 Diabetes During Hypoglycemia
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Brain Activation During Working Memory Is Altered in Patients With Type 1 Diabetes During Hypoglycemia
Nicolas R. Bolo, Gail Musen, Alan M. Jacobson, Katie Weinger, Richard L. McCartney, Veronica Flores, Perry F. Renshaw, Donald C. Simonson
Diabetes Dec 2011, 60 (12) 3256-3264; DOI: 10.2337/db11-0506

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Brain Activation During Working Memory Is Altered in Patients With Type 1 Diabetes During Hypoglycemia
Nicolas R. Bolo, Gail Musen, Alan M. Jacobson, Katie Weinger, Richard L. McCartney, Veronica Flores, Perry F. Renshaw, Donald C. Simonson
Diabetes Dec 2011, 60 (12) 3256-3264; DOI: 10.2337/db11-0506
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • circRNA_010383 Acts as a Sponge for miR-135a, and Its Downregulated Expression Contributes to Renal Fibrosis in Diabetic Nephropathy
  • CaM Kinase II-δ Is Required for Diabetic Hyperglycemia and Retinopathy but Not Nephropathy
  • Connectivity Mapping Identifies BI-2536 as a Potential Drug to Treat Diabetic Kidney Disease
Show more Complications

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.